Can a drug stop lung cancer before it starts? new trial aims to find out
NCT ID NCT04789681
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug canakinumab can prevent lung cancer in 50 people who have suspicious lung nodules that haven't gone away. Participants receive the drug and are monitored for nodule shrinkage and cancer development. The goal is to see if this approach can stop lung cancer from forming.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radiation hotspots may boost lung cancer treatment — a trial puts it to the test
- Could a simple assessment help older lung cancer patients tolerate chemo better?
- New PET tracer could spot cancers that standard scans overlook
- Could a muscle relaxant help fight lung cancer? scientists test papaverine with standard therapy
- Can a conversation aid empower lung cancer patients?
- Can couples coping together ease the burden of advanced cancer?